KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Capital Expenditures: 2009-2025

Historic Capital Expenditures for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $28.4 million.

  • Biomarin Pharmaceutical's Capital Expenditures rose 54.08% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.8 million, marking a year-over-year decrease of 13.67%. This contributed to the annual value of $85.4 million for FY2024, which is 11.65% down from last year.
  • Biomarin Pharmaceutical's Capital Expenditures amounted to $28.4 million in Q3 2025, which was up 66.35% from $17.1 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Capital Expenditures high stood at $35.7 million for Q4 2022, and its period low was $16.8 million during Q1 2025.
  • In the last 3 years, Biomarin Pharmaceutical's Capital Expenditures had a median value of $21.6 million in 2023 and averaged $22.2 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Capital Expenditures crashed by 37.10% in 2021 and then spiked by 56.40% in 2022.
  • Biomarin Pharmaceutical's Capital Expenditures (Quarterly) stood at $28.7 million in 2021, then climbed by 24.18% to $35.7 million in 2022, then fell by 18.97% to $28.9 million in 2023, then tumbled by 32.46% to $19.5 million in 2024, then skyrocketed by 54.08% to $28.4 million in 2025.
  • Its last three reported values are $28.4 million in Q3 2025, $17.1 million for Q2 2025, and $16.8 million during Q1 2025.